Table 2 Demographic and clinical characteristics of patients in the follow-up and external validation sets
Variable | Follow-up set (n = 355) | External validation set (n = 221) |
|---|---|---|
Age, median (IQR), year | 28.0 (25.0–32.0) | 30.0 (27.5–34.0) |
follow-up duration, median (IQR), month | 64.0 (42.0–83.0) | 22.0 (14.5–27.0) |
Death or heart failure, No. (%) | ||
No | 266 (74.9) | 183 (82.8) |
Yes | 89 (25.1) | 38 (17.2) |
Death, No. (%) | ||
No | 343 (96.6) | 217 (98.2) |
Yes | 12 (3.4) | 4 (1.8) |
Heart failure, No. (%) | ||
No | 278 (78.3) | 187 (84.6) |
Yes | 77 (21.7) | 34 (15.4) |
Mild preeclampsia, No. (%) | ||
No | 348 (98.0) | 210 (95.0) |
Yes | 7 (2.0) | 11 (5.0) |
Severe preeclampsia, No. (%) | ||
No | 308 (86.8) | 176 (79.6) |
Yes | 47 (13.2) | 45 (20.4) |
Eclampsia with pregnancy/delivery, No. (%) | ||
No | 318 (89.6) | 194 (87.8) |
Yes | 37 (10.4) | 27 (12.2) |
Eclampsia with pre-existing HTN, No. (%) | ||
No | 344 (96.9) | 212 (95.9) |
Yes | 11 (3.1) | 9 (4.1) |
Postpartum haemorrhage, No. (%) | ||
No | 341 (96.1) | 201 (91.0) |
Yes | 14 (3.9) | 20 (9.0) |
Multiple pregnancies, No. (%) | ||
No | 339 (95.5) | 192 (86.9) |
Yes | 16 (4.5) | 29 (13.1) |
Premature rupture of membranes, No. (%) | ||
No | 336 (95.5) | 205 (92.8) |
Yes | 16 (4.5) | 16 (7.2) |
Type I respiratory failure, No. (%) | ||
No | 331 (93.2) | 207 (93.7) |
Yes | 24 (6.8) | 14 (6.3) |
Type II respiratory failure, No. (%) | ||
No | 353 (99.4) | 219 (99.1) |
Yes | 2 (0.6) | 2 (0.9) |
Arrhythmia, No. (%) | ||
No | 220 (62.0) | 139 (62.9) |
Yes | 135 (38.0) | 82 (37.1) |
Patent ductus arteriosus, No. (%) | ||
No | 343 (96.6) | 209 (94.6) |
Yes | 12 (3.4) | 12 (5.4) |
Ventricular septal defect, No. (%) | ||
No | 285 (80.3) | 198 (89.6) |
Yes | 70 (19.7) | 23 (10.4) |
Atrial septal defect, No. (%) | ||
No | 257 (72.4) | 182 (82.4) |
Yes | 98 (27.6) | 39 (17.6) |
Pulmonary embolism, No. (%) | ||
No | 347 (97.7) | 220 (99.5) |
Yes | 8 (2.3) | 1 (0.5) |
Endocarditis, No. (%) | ||
No | 354 (99.7) | 220 (99.5) |
Yes | 1 (0.3) | 1 (0.5) |
Myocardiopathy, No. (%) | ||
No | 340 (95.8) | 219 (99.1) |
Yes | 15 (4.2) | 2 (0.9) |
Rheumatic heart disease, No. (%) | ||
No | 326 (91.8) | 212 (95.9) |
Yes | 29 (8.2) | 9 (4.1) |
Congenital heart disease, No. (%) | ||
No | 150 (42.3) | 134 (60.6) |
Yes | 205 (57.7) | 87 (39.4) |
Eisenmenger syndrome, No. (%) | ||
No | 321 (90.4) | 210 (95.0) |
Yes | 34 (9.6) | 11 (5.0) |
Gestational diabetes mellitus, No. (%) | ||
No | 318 (89.6) | 194 (87.8) |
Yes | 37 (10.4) | 27 (12.2) |
Infection, No. (%) | ||
No | 313 (88.2) | 170 (87.8) |
Yes | 42 (11.8) | 51 (12.2) |
Systemic lupus erythematosus, No. (%) | ||
No | 343 (96.6) | 211 (95.5) |
Yes | 12 (3.4) | 10 (4.5) |
Liver insufficiency, No. (%) | ||
No | 349 (98.3) | 209 (94.6) |
Yes | 6 (1.7) | 12 (5.4) |
Left to right shunt, No. (%) | ||
No | 344 (96.9) | 209 (94.6) |
Yes | 11 (3.1) | 12 (5.4) |
Right-to-left shunt, No. (%) | ||
No | 351 (98.9) | 217 (98.2) |
Yes | 4 (1.1) | 4 (1.8) |
Premature delivery, No. (%) | ||
No | 152 (42.8) | 87 (39.4) |
Yes | 152 (42.8) | 107 (48.4) |
PH classification, No. (%) | ||
Group 1 | 294 (82.8) | 191 (86.4) |
Group 2 | 50 (14.1) | 18 (8.1) |
Group 3 | 2 (0.6) | 2 (0.9) |
Group 4 | 2 (0.6) | 0 (0.0) |
Group 5 | 7 (2.0) | 10 (4.5) |
Pregnancy outcome, No. (%) | ||
Termination of pregnancy | 51 (14.4) | 26 (11.8) |
Vaginal delivery | 26 (7.3) | 20 (9.0) |
Spinal and/or epidural for C-section | 240 (67.6) | 164 (74.2) |
General anaesthesia for C-section | 38 (10.7) | 11 (5.0) |
Cardiac surgery, No. (%) | ||
No | 339 (95.5) | 204 (92.3) |
Repair of heart defect | 16 (4.5) | 17 (7.7) |
NYHA functional class, No. (%) | ||
I/II | 203 (57.2) | 155 (70.1) |
III | 91 (25.6) | 39 (17.6) |
IV | 61 (17.2) | 27 (12.2) |
NT-proBNP, No. (%), ng/L | ||
< 1400 | 268 (75.5) | 177 (80.1) |
≥ 1400 | 87 (24.5) | 44 (19.9) |
Gestation times, median (IQR), times | 2.0 (1.0–3.0) | 2.0 (1.0–3.0) |
Parity, median (IQR), times | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) |
Troponin, median (IQR), ng/mL | 0.01 (0.00–0.03) | 0.01 (0.00–0.15) |
Prothrombin time, median (IQR), s | 10.1 (9.5–10.8) | 10.4 (9.7–11.2) |
APTT, median (IQR), s | 29.2 (26.8–32.4) | 27.9 (26.1–30.7) |
Thrombin time, median (IQR), s | 13.8 (12.7–15.9) | 14.3 (13.1–15.6) |
Fibrinogen, median (IQR), g/L | 3.7 (3.1–4.3) | 3.8 (3.2–4.3) |
RBC, median (IQR), × 1012/L | 3.9 (3.5–4.3) | 3.8 (3.4–4.2) |
Haemoglobin, median (IQR), g/L | 112.0 (101.0–124.0) | 111.5 (100.0–123.0) |
Platelet, median (IQR), × 109/L | 190.0 (129.8–237.0) | 179.0 (137.0–228.0) |
D-Dimer, median (IQR), mg/L | 0.7 (0.4–1.3) | 0.6 (0.3–1.6) |
RVD, median (IQR), mm | 22.0 (18.0–29.0) | 20.0 (18.0–24.0) |
LVDs, median (IQR), mm | 38.0 (30.0–46.0) | 40.0 (33.0–46.0) |
mPAD, median (IQR), mm | 23.0 (21.0–27.0) | 23.0 (21.0–26.0) |
AOD, median (IQR), mm | 22.0 (20.0–26.0) | 25.0 (20.0–25.0) |
EF, median (IQR), % | 63.0 (60.0–65.0) | 63.0 (60.0–66.0) |
PASP, median (IQR), mm Hg | 53.0 (43.0–79.0) | 44.0 (37.0–65.0) |